Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04855136
Title Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma (KarMMa-7)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Celgene

multiple myeloma


Iberdomide + Idecabtagene Vicleucel

Idecabtagene Vicleucel + LY3039478

Bortezomib + Dexamethasone + Idecabtagene Vicleucel + Pomalidomide

Age Groups: adult | senior
Covered Countries USA | ESP

No variant requirements are available.